Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists hunt for genetic clues in blood and urine to personalize lung cancer care

NCT ID NCT02597738

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study collects blood, urine, and tissue samples from 330 adults with advanced lung or head and neck cancer to improve precision medicine. Researchers will analyze genetic changes in these samples and grow some tumors in mice to compare DNA. The goal is to refine liquid biopsies and identify biomarkers for better diagnosis and treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 330 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Jan 2016

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Cohort A (Lung/Head and Neck Cancer Group) Inclusion criteria: 1. Unresectable metastatic lung cancer or head and neck cancer or other solid tumor malignancy 2. Current or Former Smokers with greater than or equal to 10 pack year smoking history 3. Candidates for standard or experimental treatment as determined by their treating physician 4. Age 18 years and older 5. Must sign an informed consent approved by the UAMS Institutional Review Board (IRB) Cohort A (Lung/Head and Neck Cancer Group) Exclusion criteria: 1. Any other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the treatment regimen 2. Existing diagnosis or evidence of Hepatits C, Rheumatoid Arthritis or any previous solid organ transplant. 3. Existing diagnosis or evidence of organic brain syndrome that might preclude participation in the full protocol 4. Existing diagnosis or history of significant impairment of basal cognitive function that might preclude participation in the full protocol 5. Other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the treatment regimen Cohort B (Chronic Inflammatory disease) Inclusion criteria: 1. Chronic inflammatory disease including but not limited to: * Systematic Lupus Erythematosus * Rheumatoid arthritis * Hepatitis C * Ankylosing Sponsylitis * Scleroderma 2. No history of smoking or quit smoking within the last six months 3. Age 18 years and older 4. Must sign an informed consent approved by the UAMS Institutional Review Board (IRB) Cohort B (Chronic inflammatory disease) Exclusion criteria: 1\. Any other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the treatment regimen. 2. Existing diagnosis or evidence of organic brain syndrome that might preclude participation in the full protocol. 3\. Existing diagnosis or history of significant impairment of basal cognitive function that might preclude participation in the full protocol. 4\. Other current malignancy(s). Subjects with prior history at any time of any in situ cancer, including lobular carcinoma of the breast in situ, cervical cancer in situ, atypical melanocytic hyperplasia or Clark I melanoma in situ or basal or squamous skin cancer are eligible, provided they are disease-free at the time of registration. Subjects with other malignancies are eligible if they have been continuously disease free for ≥ 5 years prior to the time of registration. 5\. No current steroid treatment or treatment within the last 3 months. Cohort C (At risk for lung cancer) Inclusion criteria: 1. Age 45-74 years 2. Former or current smokers with a 30 or more pack-years of cigarette smoking history 3. Must sign an informed consent approved by the UAMS Institutional Review Board (IRB) Cohort C (At risk for lung cancer) Exclusion criteria: 1. Other current malignancy(s). Subjects with prior history at any time of any in situ cancer, including lobular carcinoma of the breast in situ, cervical cancer in situ, atypical melanocytic hyperplasia or Clark I melanoma in situ or basal or squamous skin cancer are eligible, provided they are disease-free at the time of registration. Subjects with other malignancies are eligible if they have been continuously disease free for ≥ 5 years prior to the time of registration. 2. History of lung cancer 3. History of removal of any portion of the lung, excluding needle biopsy 4. Unexplained weight loss of more than 15 pounds in the 12 months prior to eligibility assessment 5. Recent hemoptysis 6. Pneumonia or acute respiratory infection treated with antibiotics in the 12 weeks prior to eligibility assessment. 7. History of abnormal chest CT examination suspicious for cancer in the 18 months prior to eligibility assessment. 9\. Chronic inflammatory disease including but not limited to: * Systematic Lupus Erythematosus * Rheumatoid arthritis * Hepatitis C * Ankylosing Sponsylitis * Scleroderma Cohort D (healthy people who exercise) Inclusion criteria: 1. Age 18 years and older 2. Must sign an informed consent approved by the UAMS Institutional Review Board (IRB) 3. Must complete and self-report vigorous exercise for 30 minutes Cohort D (healthy people who exercise) Exclusion criteria: 1\. People will be excluded if they have self reported any of the following conditions: diabetes, heart disease, autoimmune disorders or hepatitis. Cohort E (lung cancer with planned resection) Inclusion criteria: 1. Age 18 years and older 2. Must sign an informed consent approved by the UAMS Institutional Review Board (IRB) 3. Lung cancer with planned resection. Cohort E (lung cancer with planned resection) Exclusion criteria: 1. Any other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the protocol 2. Existing diagnosis or evidence of Hepatits C, Rheumatoid Arthritis or any previous solid organ transplant. Cohort F (Any solid tumor cancer with radiation therapy) Inclusion criteria: 1. Age 18 years and older 2. Must sign an informed consent approved by the UAMS Institutional Review Board (IRB) 3. Any solid tumor cancer and will receive radiation therapy. Cohort F (Any solid tumor cancer with radiation therapy) Exclusion criteria: 1\. Any other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the protocol 3. Existing diagnosis or evidence of Hepatits C, Rheumatoid Arthritis or any previous solid organ transplant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic inflammatory disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas, 72205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.